Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure
Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure
复制标题
DOI:
10.1016/j.jchf.2014.09.001
复制
发表时间:
2014-12-01
影响因子:
13
通讯作者:
Solomon, Scott D.
中科院分区:
文献类型:
--
作者:
Vardeny, Orly;Miller, Ryan;Solomon, Scott D.
Neprilysin is an enzyme that contributes to the breakdown of the biologically active natriuretic peptides and several other vasoactive compounds. Inhibiting neprilysin has been a therapeutic target for several compounds that have been tested in cardiovascular disease, including ecadotril, candoxatril, omapatrilat, and LCZ696. Although ecadotril, candoxatril, and omapatrilat were initially tested in hypertension and/or heart failure, lack of efficacy and side effects led to discontinuation of their development. LCZ696 (sacubitril valsartan) is a first-in-class angiotensin receptor neprilysin inhibitor that has been developed for use in heart failure. This compound is composed of 2 molecular moieties in a single crystalline complex-the angiotensin receptor blocker valsartan and a neprilysin inhibitor prodrug-and has now been tested in hypertension, in a phase 2 trial in heart failure with preserved ejection fraction, and has demonstrated greater efficacy than enalapril in a phase 3 trial in heart failure with reduced ejection fraction. Its ability to inhibit the renin-angiotensin-aldosterone axis and augment the endogenous natriuretic peptide system provides a distinctive mechanism of action in cardiovascular disease. (C) 2014 by the American College of Cardiology Foundation.